0001209191-19-001611.txt : 20190103 0001209191-19-001611.hdr.sgml : 20190103 20190103210205 ACCESSION NUMBER: 0001209191-19-001611 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181231 FILED AS OF DATE: 20190103 DATE AS OF CHANGE: 20190103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mates Sharon CENTRAL INDEX KEY: 0001585699 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36274 FILM NUMBER: 19508213 MAIL ADDRESS: STREET 1: C/O INTRA-CELLULAR THERAPIES, INC. STREET 2: 3960 BROADWAY CITY: NEW YORK STATE: NY ZIP: 10032 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc. CENTRAL INDEX KEY: 0001567514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364742850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 212-923-3344 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: Oneida Resources Corp. DATE OF NAME CHANGE: 20130122 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-12-31 0 0001567514 Intra-Cellular Therapies, Inc. ITCI 0001585699 Mates Sharon C/O INTRA-CELLULAR THERAPIES, INC. 430 EAST 29TH STREET NEW YORK NY 10016 1 1 0 0 Chairman, President & CEO Common Stock 2018-12-31 4 A 0 17478 0.00 A 1156185 D Common Stock 2019-01-02 4 S 0 17478 11.09 D 1138707 D Common Stock 2019-01-03 4 M 0 11258 A 1149965 D Common Stock 2019-01-03 4 M 0 34340 A 1184305 D Restricted Stock Units 2019-01-03 4 M 0 11258 0.00 D Common Stock 11258 11258 D Restricted Stock Units 2019-01-03 4 M 0 34340 0.00 D Common Stock 34340 68681 D Represents shares issued upon the vesting of performance stock units. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 18, 2018. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of performance stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.72 to $11.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Restricted stock units convert into common stock on a one-for-one basis. Each restricted stock unit represents a contingent right to receive one share of common stock. On January 3, 2017, the reporting person was granted 33,773 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. On January 3, 2018, the reporting person was granted 103,021 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. /s/ Lawrence J. Hineline, Attorney-in-fact 2019-01-03